| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
138,896 |
130,913 |
$7.46M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
142,712 |
50,599 |
$6.92M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
116,728 |
110,628 |
$4.73M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
54,564 |
52,313 |
$3.24M |
| 20610 |
|
35,235 |
29,542 |
$1.53M |
| 64483 |
|
7,274 |
6,707 |
$1.39M |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
39,338 |
15,565 |
$1.32M |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
62,037 |
24,401 |
$1.08M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
11,226 |
10,971 |
$992K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
16,299 |
6,727 |
$636K |
| 97161 |
|
8,807 |
8,609 |
$603K |
| 95886 |
|
4,354 |
4,149 |
$494K |
| J0897 |
Injection, denosumab, 1 mg |
1,256 |
1,183 |
$470K |
| 72100 |
|
15,806 |
15,448 |
$406K |
| 73564 |
|
13,531 |
12,448 |
$402K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
8,320 |
2,039 |
$362K |
| 73630 |
|
13,511 |
12,221 |
$306K |
| 27447 |
|
413 |
400 |
$301K |
| 73030 |
|
12,680 |
12,074 |
$272K |
| 64635 |
|
934 |
686 |
$236K |
| 73130 |
|
8,594 |
7,933 |
$228K |
| 99223 |
Prolong inpt eval add15 m |
1,822 |
1,784 |
$221K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
40,882 |
38,149 |
$219K |
| 36475 |
|
291 |
172 |
$204K |
| 73610 |
|
7,702 |
7,156 |
$195K |
| 64493 |
|
1,147 |
875 |
$171K |
| 73110 |
|
5,587 |
5,064 |
$167K |
| 64636 |
|
905 |
657 |
$137K |
| J7318 |
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg |
140 |
140 |
$128K |
| 95913 |
|
442 |
427 |
$111K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,984 |
1,919 |
$83K |
| 93970 |
|
714 |
698 |
$82K |
| 72040 |
|
2,891 |
2,817 |
$78K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
272 |
228 |
$76K |
| 64494 |
|
930 |
686 |
$68K |
| 99233 |
Prolong inpt eval add15 m |
981 |
639 |
$68K |
| 20611 |
|
629 |
597 |
$44K |
| 72110 |
|
1,116 |
1,109 |
$43K |
| 95911 |
|
234 |
223 |
$43K |
| 73502 |
|
1,503 |
1,460 |
$42K |
| 98980 |
|
1,102 |
1,013 |
$40K |
| 62321 |
|
229 |
203 |
$39K |
| 99222 |
Initial hospital care, per day, moderate complexity |
540 |
515 |
$39K |
| 95910 |
|
253 |
248 |
$39K |
| 73560 |
|
1,464 |
1,379 |
$37K |
| 95912 |
|
168 |
166 |
$35K |
| 64484 |
|
526 |
478 |
$35K |
| 77002 |
|
446 |
429 |
$33K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,444 |
1,095 |
$33K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
437 |
428 |
$31K |
| 36465 |
|
27 |
19 |
$29K |
| 64721 |
|
93 |
88 |
$27K |
| 20552 |
|
1,102 |
1,001 |
$27K |
| 73562 |
|
970 |
933 |
$24K |
| 99426 |
|
509 |
505 |
$23K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
911 |
875 |
$22K |
| 64495 |
|
336 |
241 |
$21K |
| 99215 |
Prolong outpt/office vis |
273 |
268 |
$18K |
| 97162 |
|
265 |
256 |
$18K |
| 27096 |
|
120 |
118 |
$17K |
| 93925 |
|
89 |
89 |
$15K |
| 95885 |
|
215 |
210 |
$14K |
| J3111 |
Injection, romosozumab-aqqg, 1 mg |
12 |
12 |
$14K |
| 97164 |
|
244 |
232 |
$12K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,647 |
2,289 |
$11K |
| 64615 |
|
159 |
141 |
$11K |
| 77073 |
|
284 |
270 |
$11K |
| J7324 |
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose |
74 |
43 |
$10K |
| 22853 |
|
40 |
36 |
$10K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,635 |
1,568 |
$10K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
427 |
263 |
$9K |
| 29848 |
|
15 |
15 |
$9K |
| 20526 |
|
117 |
107 |
$9K |
| 20550 |
|
254 |
234 |
$9K |
| 11721 |
|
430 |
411 |
$8K |
| 62323 |
|
41 |
40 |
$6K |
| 0012A |
|
180 |
177 |
$6K |
| 0011A |
|
183 |
181 |
$6K |
| J7321 |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
83 |
35 |
$5K |
| 98981 |
|
110 |
105 |
$5K |
| 73070 |
|
223 |
207 |
$5K |
| 98977 |
|
113 |
113 |
$5K |
| 99205 |
Prolong outpt/office vis |
45 |
45 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,690 |
4,196 |
$4K |
| 73140 |
|
111 |
105 |
$4K |
| Q4010 |
Cast supplies, short arm cast, adult (11 years +), fiberglass |
208 |
196 |
$4K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
349 |
338 |
$4K |
| 29075 |
|
44 |
41 |
$3K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
376 |
355 |
$3K |
| 99424 |
|
45 |
44 |
$2K |
| 98975 |
|
108 |
107 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
55 |
55 |
$2K |
| 99221 |
|
33 |
29 |
$2K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
5,317 |
3,494 |
$2K |
| Q4038 |
Cast supplies, short leg cast, adult (11 years +), fiberglass |
51 |
36 |
$1K |
| 95816 |
|
41 |
38 |
$1K |
| 99427 |
|
25 |
25 |
$1K |
| 95909 |
|
12 |
12 |
$1K |
| 76942 |
|
42 |
38 |
$1K |
| 20553 |
|
40 |
39 |
$1K |
| 93971 |
|
14 |
13 |
$1K |
| 73600 |
|
62 |
54 |
$1K |
| 72050 |
|
25 |
25 |
$1K |
| 73565 |
|
28 |
26 |
$907.96 |
| 73100 |
|
33 |
30 |
$819.23 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
197 |
197 |
$736.60 |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
13 |
12 |
$675.98 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
147 |
142 |
$359.71 |
| 20600 |
|
13 |
12 |
$267.45 |
| 20605 |
|
13 |
13 |
$228.63 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
32 |
31 |
$200.33 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
127 |
118 |
$189.99 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
28 |
17 |
$116.04 |
| 99499 |
|
87 |
81 |
$0.22 |
| 91301 |
|
129 |
121 |
$0.00 |
| 99024 |
|
42 |
36 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
282 |
254 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
484 |
421 |
$0.00 |